NNNN NNNN
Company Profile ↓Company Overview
NNNN (NNNN) is a publicly traded company listed on with a market capitalization of $445.50M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Generates a return on equity of 21.2%, reflecting efficient use of shareholder capital.
Return on capital employed stands at 19.1%.
Maintains a net profit margin of 74.1%.
Recent Developments
- Dec 2025 Revenue of $8.65M (+5.6% YoY); net profit $6.40M.
- Trailing 12 Months Year-on-year growth — revenue +5.6%, earnings +169.9%.
- 5-Year Trend Long-term compounding — revenue CAGR -28.4%, profit CAGR -13.8%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -28.39% |
| 1 Year: | 5.64% |
Compounded Profit Growth
| 5 Years: | -13.84% |
| 1 Year: | 169.86% |
Stock Price Performance
| 1 Year: | -77.21% |
| 6 Months: | -62.71% |
| 3 Months: | -65.24% |
| 1 Month: | -13.25% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)39.40 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 21.2%.
- Excellent profit margin of 74.1%.
CONS
- Trading at a high P/E of 187.8.
- Revenue declined at -28.4% CAGR over 5 years.
- Earnings shrank at -13.8% CAGR over 5 years.
- Trading 80.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 23.54M | 6.71M | 8.19M | 8.65M |
| Cost of Revenue | - | 10.98M | 3.35M | 2.30M | 1.10M |
| Gross Profit | - | 12.56M | 3.36M | 5.89M | 7.54M |
| Operating Expenses | - | 2.37M | 1.40M | 3.89M | 1.78M |
| Operating Income | - | 10.20M | 1.96M | 2.00M | 5.77M |
| EBITDA | - | 10.03M | 1.97M | 2.00M | 5.77M |
| Interest Expense | 0 | 8.00K | 0 | 0 | - |
| Pretax Income | - | 10.01M | 2.25M | 2.37M | 6.40M |
| Tax Provision | - | 0 | 0 | 0 | 0 |
| Net Income | - | 10.01M | 2.25M | 2.37M | 6.40M |
| Diluted EPS | 0.03 | 0.07 | 0.01 | 0.05 | - |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 13.96M | 15.81M | 18.92M | 30.24M |
| Current Assets | - | 13.94M | 15.75M | 18.53M | 30.24M |
| Cash & Equivalents | - | 7.10M | 9.69M | 11.76M | 7.77M |
| Inventory | 0 | 353.87K | 0 | - | - |
| Receivables | - | 0 | 1.88M | 1.06M | 3.66M |
| Total Liabilities | - | 1.41M | 993.06K | 1.73M | 87.84K |
| Current Liabilities | - | 1.41M | 993.06K | 1.73M | 87.84K |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | - | - | - | - |
| Total Equity | - | 12.55M | 14.82M | 17.19M | 30.16M |
| Shares Outstanding | - | 43.89M | 43.89M | 43.89M | 43.89M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | 4.45M | 898.37K | 2.08M | -6.74M |
| Investing Cash Flow | - | -1.53M | 1.73M | 337.10K | -4.20M |
| Financing Cash Flow | - | 0 | -42.84K | -344.61K | 6.95M |
| Capital Expenditure | - | - | - | - | - |
| Free Cash Flow | - | 4.45M | 898.37K | 2.08M | -6.74M |
| Net Change in Cash | - | 2.92M | 2.59M | 2.07M | -3.99M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | 53.4% | 50.1% | 71.9% | 87.2% |
| Operating Margin % | - | 43.3% | 29.2% | 24.4% | 66.7% |
| Net Margin % | - | 42.5% | 33.6% | 29.0% | 74.1% |
| ROE % | - | 79.8% | 15.2% | 13.8% | 21.2% |
| ROCE % | - | 81.3% | 13.2% | 11.6% | 19.1% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for NNNN
Assessing Anbio Biotechnology (NNNN) Valuation After Strong Recent Share Price Momentum - simplywall.st
<a href="https://news.google.com/rss/articles/CBMi6AFBVV95cUxPNTJaMC1SSFpMcFpoRTBfZ0pmb0N0NEFFS2hnVDd6RXU2ZEo3YmZra2FiOTlnOGdtRWdaeXdOX0t2Qkw3cDVPMDdLV25GV0VKbHZ2ajZVS2YtYkFUWnc3dGZmUTNzaXF1QWpSaWxGeTM3cFRXLU85OWFDbXUwQzRQWURyZ3M2bHVhanQ2QW…
Anbio Biotechnology (NNNN) Stock Forecast and Price Target 2026 - MarketBeat
<a href="https://news.google.com/rss/articles/CBMiZkFVX3lxTFBVMk1zcWFoN0JralVPd3VOMXVSZmNBa2ZRSzlqeUluSkZ4aWRyRzE2V09WVXZFeVBURlNpV1kxTUJDREE0eWFaNk01XzdhdkdKNmU1Nm5nYjd3bTgzOE05MlA1OTZtQQ?oc=5" target="_blank">Anbio Biotechnology (NNNN) St…
Anbio Biotechnology Revenue Breakdown – NASDAQ:NNNN - TradingView
<a href="https://news.google.com/rss/articles/CBMid0FVX3lxTFBtRF9SeFFxUG85WDM1Yno2UmR3Um1saEFlZTlkZ052dGFzZWdJb0VDN1RQNmJkNXI0eUZBWlotTFJzdE1YWDViR2NJX1dnbkJCTWVrc1hWb3pQTkhkMlo1TVNTNUlveks1d283N3RQUl9fM3pwWDJj?oc=5" target="_blank">Anbio B…
(NNNN) as a Liquidity Pulse for Institutional Tactics - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMiygFBVV95cUxQd1ZZRFBIX2hpN2dkay1xVlNmWlhLRUdMbTVKTFlYbmNYZm9MSTB1TmMwTHF0d1dQQjF4bVlucFNTSWxQY1JOS3dsUUp5enhHZ2Z1V1loUnc4cEUwSVN4Z1hWRDlHWnpuU3Y1UFNySW9Ja2M0aGpQU3RWUG5RMXFHakxLQ1M5ME9zcVVoc1…
Anbio Biotechnology: Improved Margins, Still Priced For Growth That Isn't Showing Up - Seeking Alpha
<a href="https://news.google.com/rss/articles/CBMiwAFBVV95cUxNb2V5ZkdCSDl3MWVheWhudnNHUG1lM20tWUJQQk95SlVGV0FwRmlSX25xYzktZHVfbEU2YWxKMDNDck56RjJXVnRzVFJaWFJOcG5hN2VQZjd5WEFYUU9JUkJiQkN4aHJuX1dhRWdvd2p0aHZQNWhCcnhhUXl0dVVQQWNhYWxLd3ZLNmtuVG…
Top 3 Health Care Stocks That May Rocket Higher In July - Legend Biotech (NASDAQ:LEGN), Anbio Biotechnolo - Benzinga
<a href="https://news.google.com/rss/articles/CBMivwFBVV95cUxOTnZnSWctbl9rb3BnWWNjSUlZNk9fX21yMmVZRTRfTFlzNDNKcklOd3UyWGQzd2Z3X3hDLVZUNkxmcU1xdVR5VTJCdDdMYXFucm96Zl9SZnNKcHI0YmFWNUlHdlhOZC1SOG5SX241eXUxd29YeDlVSzRCRGVQVzBLUW1Db1psb2pjaGJVb0…
NNNN — Frequently Asked Questions
What is the current share price of NNNN?
As of 2026-08-05 17:25 PDT, NNNN trades at $10.15 on NASDAQ/NYSE. Its 52-week range is $9.12 to $52.10.
What is the market capitalisation of NNNN?
NNNN has a market capitalisation of $445.50M on NASDAQ/NYSE.
What is the P/E ratio of NNNN?
NNNN trades at a trailing price-to-earnings (P/E) ratio of 187.75. Its price-to-book (P/B) ratio is 14.77.
What is the return on equity (ROE) of NNNN?
NNNN has a return on equity (ROE) of 21.24%. Its return on capital employed (ROCE) is 19.13%.
Is NNNN a good stock to buy?
This page provides a data-driven analysis of NNNN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.